Glioblastoma and Malignant Astrocytoma

Brain Tumors

Volumn , Issue , 2012, Pages 384-407

  Sarkar, Atom ^a   Chiocca, E Antonio ^b,c  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b Dardinger Neuro Oncology Center   (United States)

^c OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882467774     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-443-06967-3.00021-1     Document Type: Chapter

References (219)

1. Abe T., Terada K., Wakimoto H., et al. PTEN decreases in vivo vascularization of experimental gliomas in spite of proangiogenic stimuli. Cancer Res. 2003, 63:2300-2305.
2. Aghi M., Chiocca E.A. Contribution of bone marrow-derived cells to blood vessels in ischemic tissues and tumors. Mol. Ther. 2005, 12:994-1005.
3. Aghi M., Cohen K.S., Klein R.J., et al. Tumor stromal-derived factor-1 recruits vascular progenitors to mitotic neovasculature, where microenvironment influences their differentiated phenotypes. Cancer Res. 2006, 66:9054-9064.
4. Aghi M.K., Chiocca E.A. Phase ib trial of oncolytic herpes virus G207 shows safety of multiple injections and documents viral replication. Mol. Ther. 2009, 17:8-9.
5. Ahlbom A., Green A., Kheifets L., et al. Epidemiology of health effects of radiofrequency exposure. Environ. Health Perspect 2004, 112:1741-1754.
6. Alcantara Llaguno S., Chen J., Kwon C.H., et al. Malignant astrocytomas originate from neural stem/progenitor cells in a somatic tumor suppressor mouse model. Cancer Cell 2009, 15:45-56.
7. Alexander A.L., Lee J.E., Lazar M., et al. Diffusion tensor imaging of the brain. Neurotherapeutics 2007, 4:316-329.
8. Alvarez-Buylla A., Kohwi M., Nguyen T.M., et al. The heterogeneity of adult neural stem cells and the emerging complexity of their niche. Cold Spring Harb. Symp. Quant. Biol. 2008, 73:357-365.
9. Ammirati M., Vick N., Liao Y.L., et al. Effect of the extent of surgical resection on survival and quality of life in patients with supratentorial glioblastomas and anaplastic astrocytomas. Neurosurgery 1987, 21:201-206.
10. Armanios M.Y., Grossman S.A., Yang S.C., et al. Transmission of glioblastoma multiforme following bilateral lung transplantation from an affected donor: case study and review of the literature. Neuro. Oncol. 2004, 6:259-263.
11. Athanassiou H., Synodinou M., Maragoudakis E., et al. Randomized phase II study of temozolomide and radiotherapy compared with radiotherapy alone in newly diagnosed glioblastoma multiforme. J. Clin. Oncol. 2005, 23:2372-2377.
12. Auvinen A., Hietanen M., Luukkonen R., et al. Brain tumors and salivary gland cancers among cellular telephone users. Epidemiology (Cambridge MA) 2002, 13:356-359.
13. Bachoo R.M., Maher E.A., Ligon K.L., et al. Epidermal growth factor receptor and Ink4a/Arf: convergent mechanisms governing terminal differentiation and transformation along the neural stem cell to astrocyte axis. Cancer Cell 2002, 1:269-277.
14. Baldwin R.T., Preston-Martin S. Epidemiology of brain tumors in childhood - a review. Toxicol. Appl. Pharmacol. 2004, 199:118-131.
15. Barker F.G., Huhn S.L., Prados M.D. Clinical characteristics of long-term survivors of glioma. The gliomas 1998, 710-722. WB Saunders, Philadelphia, PA. M.S. Berger, C.B. Wilson (Eds.).
16. Bellail A.C., Hunter S.B., Brat D.J., et al. Microregional extracellular matrix heterogeneity in brain modulates glioma cell invasion. Int. J. Biochem. Cell Biol. 2004, 36:1046-1069.
17. Bennett M.R. Mechanisms of p53-induced apoptosis. Biochem. Pharmacol. 1999, 58:1089-1095.
18. Biernat W., Kleihues P., Yonekawa Y., et al. Amplification and overexpression of MDM2 in primary (de novo) glioblastomas. J. Neuropathol. Exp. Neurol. 1997, 56:180-185.
19. Blettner M., Schlehofer B., Samkange-Zeeb F., et al. Medical exposure to ionising radiation and the risk of brain tumours: Interphone Study Group, Germany. Eur. J. Cancer 2007, 43:1990-1998.
20. Bondy M., Wiencke J., Wrensch M., et al. Genetics of primary brain tumors: a review. J. Neurooncol. 1994, 18:69-81.
21. Brem H., Piantadosi S., Burger P.C., et al. Placebo-controlled trial of safety and efficacy of intraoperative controlled delivery by biodegradable polymers of chemotherapy for recurrent gliomas. The Polymer-brain Tumor Treatment Group. Lancet 1995, 345:1008-1012.
22. Brunberg J.A., Chenevert T.L., McKeever P.E., et al. In vivo MR determination of water diffusion coefficients and diffusion anisotropy: correlation with structural alteration in gliomas of the cerebral hemispheres. Am. J. Neuroradiol. 1995, 16:361-371.
23. Buatti J., Ryken T.C., Smith M.C., et al. Radiation therapy of pathologically confirmed newly diagnosed glioblastoma in adults. J. Neurooncol. 2008, 89:313-337.
24. Buckner J.C. Factors influencing survival in high-grade gliomas. Semin. Oncol. 2003, 30:10-14.
25. Bunin G.R., Kuijten R.R., Buckley J.D., et al. Relation between maternal diet and subsequent primitive neuroectodermal brain tumors in young children. N. Engl. J. Med. 1993, 329:536-541.
26. Cairncross J.G., Ueki K., Zlatescu M.C., et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J. Natl. Cancer Inst. 1998, 90:1473-1479.
27. Canoll P., Goldman J.E. The interface between glial progenitors and gliomas. Acta. Neuropathol. 2008, 116:465-477.
28. Caresia A.P., Castell-Conesa J., Negre M., et al. Thallium-201SPECT assessment in the detection of recurrences of treated gliomas and ependymomas. Clin. Transl. Oncol. 2006, 8:750-754.
29. Cazenave C., Reid S., Virapongse C., et al. Reactive gliosis simulating butterfly glioma: a neuroradiological case study. Neurosurgery 1986, 19:816-819.
30. CBTRUS, 2008. Statistical report: primary brain tumors in the United States, 2000-2004. Central Brain Tumor Registry of the United States, Hinsdale, IL.
31. Chakravarti A., Dicker A., Mehta M. The contribution of epidermal growth factor receptor (EGFR) signaling pathway to radioresistance in human gliomas: a review of preclinical and correlative clinical data. Int. J. Radiat. Oncol. Biol. Phys. 2004, 58:927-931.
32. Chang J., Thakur S.B., Huang W., et al. Magnetic resonance spectroscopy imaging (MRSI) and brain functional magnetic resonance imaging (fMRI) for radiotherapy treatment planning of glioma. Technol. Cancer Res. Treat. 2008, 7:349-362.
33. Chang S.M., Barker F.G. Marital status, treatment, and survival in patients with glioblastoma multiforme: a population based study. Cancer 2005, 104:1975-1984.
34. Chang S.M., Parney I.F., Huang W., et al. Patterns of care for adults with newly diagnosed malignant glioma. JAMA 2005, 293:557-564.
35. Chen H., Shah A.S., Girgis R.E., et al. Transmission of glioblastoma multiforme after bilateral lung transplantation. J. Clin. Oncol. 2008, 26:3284-3285.
36. Chen H., Ward M.H., Tucker K.L., et al. Diet and risk of adult glioma in eastern Nebraska, United States. Cancer Causes Control 2002, 13:647-655.
37. Chi A., Norden A.D., Wen P.Y. Inhibition of angiogenesis and invasion in malignant gliomas. Expert Rev. Anticancer Ther. 2007, 7:1537-1560.
38. Chiocca E.A., Aghi M., Fulci G. Viral therapy for glioblastoma. Cancer J. 2003, 9:167-179.
39. Chiocca E.A., Smith K.M., McKinney B., et al. A phase I trial of Ad.hIFN-beta gene therapy for glioma. Mol. Ther. 2008, 16:618-626.
40. Chiocca E.A. The host response to cancer virotherapy. Curr. Opin. Mol. Ther. 2008, 10:38-45.
41. Christensen H.C., Schüz J., Kosteljanetz M., et al. Cellular telephones and risk for brain tumors: a population-based, incident case-control study. Neurology 2005, 64:1189-1195.
42. Ciric I., Ammirati M., Vick N., et al. Supratentorial gliomas: surgical considerations and immediate postoperative results. Gross total resection versus partial resection. Neurosurgery 1987, 21:21-26.
43. Cobbs C.S., Harkins L., Samanta M., et al. Human cytomegalovirus infection and expression in human malignant glioma. Cancer Res. 2002, 62:3347-3350.
44. Curran W.J., Scott C.B., Horton J., et al. Recursive partitioning analysis of prognostic factors in three Radiation Therapy Oncology Group malignant glioma trials. J. Natl. Cancer Inst. 1993, 85:704-710.
45. DeLaney T.F. Clinical proton radiation therapy research at the Francis H. Burr Proton Therapy Center. Technol. Cancer Res. Treat. 2007, 6:61-66.
46. Dell'Albani P. Stem cell markers in gliomas. Neurochem. Res. 2008, 33:2407-2415.
47. Demuth T., Rennert J.L., Hoelzinger D.B., et al. Glioma cells on the run - the migratory transcriptome of 10 human glioma cell lines. BMC Genomics 2008, 9:54.
48. Derlon J.M., Bourdet C., Bustany P., et al. [11C]L-methionine uptake in gliomas. Neurosurgery 1989, 25:720-728.
49. Di Costanzo A., Scarabino T., Trojsi F., et al. Proton M R spectroscopy of cerebral gliomas at 3 T: spatial heterogeneity, and tumour grade and extent. Eur. Radiol. 2008, 18:1727-1735.
50. Doetsch F., Petreanu L., Caille I., et al. EGF converts transit-amplifying neurogenic precursors in the adult brain into multipotent stem cells. Neuron. 2002, 36:1021-1034.
51. Donahue B., Scott C.B., Nelson J.S., et al. Influence of an oligodendroglial component on the survival of patients with anaplastic astrocytomas: a report of Radiation Therapy Oncology Group 83-02. Int. J. Radiat. Oncol. Biol. Phys. 1997, 38:911-914.
52. Earnest F., Kelly P.J., Scheithauer B.W., et al. Cerebral astrocytomas: histopathologic correlation of MR and CT contrast enhancement with stereotactic biopsy. Radiology 1988, 166:823-827.
53. Ekstrand A.J., Longo N., Hamid M.L., et al. Functional characterization of an EGF receptor with a truncated extracellular domain expressed in glioblastomas with EGFR gene amplification. Oncogene 1994, 9:2313-2320.
54. Ekstrand A.J., Sugawa N., James C.D., et al. Amplified and rearranged epidermal growth factor receptor genes in human glioblastomas reveal deletions of sequences encoding portions of the N- and/or C-terminal tails. Proc. Natl. Acad. Sci. USA 1992, 89:4309-4313.
55. Fan G., Sun B., Wu Z., et al. In vivo single-voxel proton M R spectroscopy in the differentiation of high-grade gliomas and solitary metastases. Clin. Radiol. 2004, 59:77-85.
56. Feychting M., Anders A. Radiofrequency fields and glioma. Principles and practices of neuro-oncology: A multidisciplinary approach 2010, New York, Demos Medical. M. Mehta, S. Chang, H. Newton (Eds.).
57. Forsyth P.A., Kelly P.J., Cascino T.L., et al. Radiation necrosis or glioma recurrence: is computer-assisted stereotactic biopsy useful?. J. Neurosurg. 1995, 82:436-444.
58. Fulci G., Chiocca E.A. The status of gene therapy for brain tumors. Expert Opin. Biol. Ther. 2007, 7:197-208.
59. Fulci G., Ishii N., Maurici D., et al. Initiation of human astrocytoma by clonal evolution of cells with progressive loss of p53 functions in a patient with a 283H TP53 germ-line mutation: evidence for a precursor lesion. Cancer Res. 2002, 62:2897-2905.
60. Fuller G.N., Scheithauer B.W. The 2007 Revised World Health Organization (WHO) Classification of Tumours of the Central Nervous System: newly codified entities. Brain Pathol. 2007, 17:304-307.
61. Gabayan A.J., Green S.B., Sanan A., et al. GliaSite brachytherapy for treatment of recurrent malignant gliomas: a retrospective multi-institutional analysis. Neurosurgery 2006, 58:701-709.
62. Galli R., Binda E., Orfanelli U., et al. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 2004, 64:7011-7021.
63. Garside R., Pitt M., Anderson R., et al. The effectiveness and cost-effectiveness of carmustine implants and temozolomide for the treatment of newly diagnosed high-grade glioma: a systematic review and economic evaluation. Health Technol. Assess 2007, 11:iii-iv. ix-221.
64. Glantz M.J., Cole B.F., Forsyth P.A., et al. Practice parameter: anticonvulsant prophylaxis in patients with newly diagnosed brain tumors. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2000, 54:1886-1893.
65. Godlewski J., Nowicki M.O., Bronisz A., et al. Targeting of the Bmi-1 oncogene/stem cell renewal factor by microRNA-128 inhibits glioma proliferation and self-renewal. Cancer Res. 2008, 68:9125-9130.
66. Gupta D.K., Chandra P.S., Ojha B.K., et al. Awake craniotomy versus surgery under general anesthesia for resection of intrinsic lesions of eloquent cortex - a prospective randomised study. Clin. Neurol. Neurosurg. 2007, 109:335-343.
67. Hambardzumyan D., Squatrito M., Carbajal E., et al. Glioma formation, cancer stem cells, and Akt signaling. Stem Cell Rev. 2008, 4:203-210.
68. Hardcastle J., Kurozumi K., Chiocca E.A., et al. Oncolytic viruses driven by tumor-specific promoters. Curr. Cancer Drug Targets 2007, 7:181-189.
69. Hardell L., Carlberg M., Mild K.H. Case-control study on cellular and cordless telephones and the risk for acoustic neuroma or meningioma in patients diagnosed 2000-2003. NeuroEpidemiology 2005, 25:120-128.
70. Hardell L., Mild K.H., Carlberg M. Case-control study on the use of cellular and cordless phones and the risk for malignant brain tumours. Int. J. Radiat. Biol. 2002, 78:931-936.
71. Hardell L., Nasman A., Pahlson A., et al. Use of cellular telephones and the risk for brain tumours: A case-control study. Int. J. Oncol. 1999, 15:113-116.
72. Hart, M.G., Grant, R., Garside, R., et al., 2008a. Chemotherapeutic wafers for high grade glioma. Cochrane Database Syst. Rev. (3), CD007294.
73. Hart, M.G., Grant, R., Garside, R., et al., 2008b. Temozolomide for high grade glioma. Cochrane Database Syst. Rev. (4), CD007415.
74. He J., Mokhtari K., Sanson M., et al. Glioblastomas with an oligodendroglial component: a pathological and molecular study. J. Neuropathol. Exp. Neurol. 2001, 60:863-871.
75. Hegi M.E., Diserens A.C., Gorlia T., et al. MGMT gene silencing and benefit from temozolomide in glioblastoma. N. Engl. J. Med. 2005, 352:997-1003.
76. Hepworth S.J., Schoemaker M.J., Muir K.R., et al. Mobile phone use and risk of glioma in adults: case-control study. BMJ 2006, 332:883-887.
77. Hermanson M., Funa K., Hartman M., et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger R N A and protein suggests the presence of autocrine and paracrine loops. Cancer Res. 1992, 52:3213-3219.
78. Hermanson M., Funa K., Koopmann J., et al. Association of loss of heterozygosity on chromosome 17p with high platelet-derived growth factor alpha receptor expression in human malignant gliomas. Cancer Res. 1996, 56:164-171.
79. Hirai T., Murakami R., Nakamura H., et al. Prognostic value of perfusion M R imaging of high-grade astrocytomas: long-term follow-up study. Am. J. Neuroradiol. 2008, 29:1505-1510.
80. Hirschberg H., Samset E., Hol P.K., et al. Impact of intraoperative M R I on the surgical results for high-grade gliomas. Min. Invasive Neurosurg. 2005, 48:77-84.
81. Hirschl R.A., Wilson J., Miller B., et al. The predictive value of low-field strength magnetic resonance imaging for intraoperative residual tumor detection. J. Neurosurg. 2009, 111(2):252-257.
82. Hochberg F., Toniolo P., Cole P. Head trauma and seizures as risk factors of glioblastoma. Neurology 1984, 34:1511-1514.
83. Hoelzinger D.B., Demuth T., Berens M.E. Autocrine factors that sustain glioma invasion and paracrine biology in the brain microenvironment. J. Natl. Cancer Inst. 2007, 99:1583-1593.
84. Hu J., Johnson K.C., Mao Y., et al. Risk factors for glioma in adults: a case-control study in northeast China. Cancer Detect Prev. 1998, 22:100-108.
85. Hu J., La Vecchia C., Negri E., et al. Diet and brain cancer in adults: a case-control study in northeast China. Int. J. Cancer 1999, 81:20-23.
86. Hu J., Little J., Xu T., et al. Risk factors for meningioma in adults: a case-control study in northeast China. Int. J. Cancer Journal 1999, 83:299-304.
87. Hur H., Jung S., Jung T.Y., et al. Cerebellar glioblastoma multiforme in an adult. J. Korean Neurosurg. Soc. 2008, 43:194-197.
88. Immonen A., Vapalahti M., Tyynelä K., et al. AdvHSV-tk gene therapy with intravenous ganciclovir improves survival in human malignant glioma: a randomised, controlled study. Mol. Ther. 2004, 10:967-972.
89. Ingber D.E. Mechanobiology and diseases of mechanotransduction. Ann. Med. 2003, 35:564-577.
90. Ingber D.E. Tensegrity I. Cell structure and hierarchical systems biology. J. Cell Sci. 2003, 116:1157-1173.
91. Ingber D.E. Tensegrity II. How structural networks influence cellular information processing networks. J. Cell Sci. 2003, 116:1397-1408.
92. Inoue R., Moghaddam K.A., Ranasinghe M., et al. Infectious delivery of the 132 kb CDKN2A/CDKN2B genomic DNA region results in correctly spliced gene expression and growth suppression in glioma cells. Gene. Ther. 2004, 11:1195-1204.
93. Inskip P.D., Mellemkjaer L., Gridley G., et al. Incidence of intracranial tumors following hospitalization for head injuries (Denmark). Cancer Causes Control 1998, 9:109-116.
94. Inskip P.D., Tarone R.E., Hatch E.E., et al. Cellular-telephone use and brain tumors. N. Engl. J. Med. 2001, 344:79-86.
95. Jeremic B., Milicic B., Grujicic D., et al. Multivariate analysis of clinical prognostic factors in patients with glioblastoma multiforme treated with a combined modality approach. J. Cancer Res. Clin. Oncol. 2003, 129:477-484.
96. Johansen C., Boice J.J., McLaughlin J., et al. Cellular telephones and cancer - a nationwide cohort study in. Denmark J. National Cancer Institute 2001, 93:203-207.
97. Juven Y., Sadetzki S. A possible association between ionizing radiation and pituitary adenoma: a descriptive study. Cancer 2002, 95:397-403.
98. Kaur B., Brat D.J., Calkins C.C., et al. Brain angiogenesis inhibitor 1 is differentially expressed in normal brain and glioblastoma independently of p53 expression. Am. J. Pathol. 2003, 162:19-27.
99. Kaye A.H., Laws E.R. Brain tumors: an encyclopedic approach 1995, Churchill Livingstone, Edinburgh.
100. Kefas B., Godlewski J., Comeau L., et al. microRNA-7 inhibits the epidermal growth factor receptor and the Akt pathway and is down-regulated in glioblastoma. Cancer Res. 2008, 68:3566-3572.
101. Kernohan J.W., Mabon R.F., Svien H.J., et al. A simplified classification of the gliomas. Mayo. Clin. Proc. 1949, 24:71-75.
102. Kirsch D.G., Tarbell N.J. New technologies in radiation therapy for pediatric brain tumors: the rationale for proton radiation therapy. Pediatr. Blood Cancer 2004, 42:461-464.
103. Kleihues P., Cavenee W.K. Pathology and genetics of tumours of the nervous system 2000, International Agency for Research on Cancer, IARC Press, Lyon.
104. Kondziolka D., Bernstein M., Resch L., et al. Significance of hemorrhage into brain tumors: clinicopathological study. J. Neurosurg. 1987, 67:852-857.
105. Kondziolka D. Stereotactic neurosurgery: what's turning people on?. Clin. Neurosurg. 2007, 54:23-25.
106. Korvenoja A., Kirveskari E., Aronen H.J., et al. Sensorimotor cortex localization: comparison of magnetoencephalography, functional M R imaging, and intraoperative cortical mapping. Radiology 2006, 241:213-222.
107. Kraus J.A., Lamszus K., Glesmann N., et al. Molecular genetic alterations in glioblastomas with oligodendroglial component. Acta. Neuropathol. 2001, 101:311-320.
108. Kunwar S., Prados M.D., Chang S.M., et al. Direct intracerebral delivery of cintredekin besudotox (IL13-PE38QQR) in recurrent malignant glioma: a report by the Cintredekin Besudotox Intraparenchymal Study Group. J. Clin. Oncol. 2007, 25:837-844.
109. Kwon C.H., Zhao D., Chen J., et al. Pten haploinsufficiency accelerates formation of high-grade astrocytomas. Cancer Res. 2008, 68:3286-3294.
110. Lacroix M., Abi-Said D., Fourney D.R., et al. A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J. Neurosurg. 2001, 95:190-198.
111. Lahkola A., Auvinen A., Raitanen J., et al. Mobile phone use and risk of glioma in 5 North European countries. Int. J. Cancer 2007, 120:1769-1775.
112. Laperriere N., Zuraw L., Cairncross G. Radiotherapy for newly diagnosed malignant glioma in adults: a systematic review. Radiother. Oncol. 2002, 64:259-273.
113. Law M., Cha S., Knopp E.A., et al. High-grade gliomas and solitary metastases: differentiation by using perfusion and proton spectroscopic MR imaging. Radiology 2002, 222:715-721.
114. Laws E.R., Parney I.F., Huang W., et al. Survival following surgery and prognostic factors for recently diagnosed malignant glioma: data from the Glioma Outcomes Project. J. Neurosurg. 2003, 99:467-473.
115. Lee M., Wrensch M., Miike R. Dietary and tobacco risk factors for adult onset glioma in the San Francisco Bay Area (California, USA). Cancer Causes Control 1997, 8:13-24.
116. Li F.P., Fraumeni J.F., Mulvihill J.J., et al. A cancer family syndrome in twenty-four kindreds. Cancer Res. 1988, 48:5358-5362.
117. Liau L.M., Black K.L., Martin N.A., et al. Treatment of a patient by vaccination with autologous dendritic cells pulsed with allogeneic major histocompatibility complex class I-matched tumor peptides. Case Report. Neurosurg. Focus. 2000, 9:e8.
118. Lonn S., Ahlbom A., Hall P., et al. Long-term mobile phone use and brain tumor risk. Am. J. Epidemiol. 2005, 161:526-535.
119. Louis D.N., Ohgaki H., Wiestler O.D., et al. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol. 2007, 114:97-109.
120. Louis D.N. Molecular pathology of malignant gliomas. Annu. Rev. Pathol. 2006, 1:97-117.
121. Lutterbach J., Sauerbrei W., Guttenberger R. Multivariate analysis of prognostic factors in patients with glioblastoma. Strahlentherapie und. Onkologie: Organ der. Deutschen. Rontgengesellschaft 2003, 179:8-15.
122. Markert J.M., Liechty P.G., Wang W., et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Mol. Ther. 2009, 17:199-207.
123. Martuza R.L., Malick A., Markert J.M., et al. Experimental therapy of human glioma by means of a genetically engineered virus mutant. Science 1991, 252:854-856.
124. McGirt M.J., Chaichana K.L., Gathinji M., et al. Independent association of extent of resection with survival in patients with malignant brain astrocytoma. J. Neurosurg. 2009, 110:156-162.
125. Online Mendelian Inheritance in Man, OMIM (TM). McKusick-Nathans Institute of Genetic Medicine, Johns Hopkins University, and National Center for Biotechnology Information 2008, National Library of Medicine Bethesda, MD. V. McKusick (Ed.).
126. McLendon R., Friedman A., Bigner D., et al. Comprehensive genomic characterization defines human glioblastoma genes and core pathways. Nature 2008, 455(7216):1061-1068. Cancer Genome Atlas Research Network.
127. Mellinghoff I.K., Wang M.Y., Vivanco I., et al. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N. Engl. J. Med. 2005, 353:2012-2024.
128. Meyer F.B., Bates L.M., Goerss S.J., et al. Awake craniotomy for aggressive resection of primary gliomas located in eloquent brain. Mayo. Clin. Proc. 2001, 76:677-687.
129. Miller G. Brain cancer. A viral link to glioblastoma?. Science 2009, 323:30-31.
130. Mukundan S., Holder C., Olson J.J. Neuroradiological assessment of newly diagnosed glioblastoma. J. Neurooncol. 2008, 89:259-269.
131. Muscat J.E., Malkin M.G., Thompson S., et al. Handheld cellular telephone use and risk of brain cancer. JAMA 2000, 284:3001-3007.
132. Mäkelä J.P., Forss N., Jääskeläinen J., et al. Magnetoencephalography in neurosurgery. Neurosurgery 2007, 61:147-165.
133. Nakada M., Nakada S., Demuth T., et al. Molecular targets of glioma invasion. Cell Mol. Life Sci. 2007, 64:458-478.
134. Narayana A., Golfinos J.G., Fischer I., et al. Feasibility of using bevacizumab with radiation therapy and temozolomide in newly diagnosed high-grade glioma. Int. J. Radiat. Oncol. Biol. Phys. 2008, 72:383-389.
135. Narayana A., Kelly P., Golfinos J., et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J. Neurosurg. 2009, 110:173-180.
136. Narod S.A., Parry D.M., Parboosingh J., et al. Neurofibromatosis type 2 appears to be a genetically homogeneous disease. Am. J. Hum. Genet. 1992, 51:486-496.
137. Nowicki M.O., Dmitrieva N., Stein A.M., et al. Lithium inhibits invasion of glioma cells; possible involvement of glycogen synthase kinase-3. Neuro. Oncol. 2008, 10:690-699.
138. Nutt C.L., Mani D.R., Betensky R.A., et al. Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. Cancer Res. 2003, 63:1602-1607.
139. Ogawa T., Shishido F., Kanno I., et al. Cerebral glioma: evaluation with methionine PET. Radiology 1993, 186:45-53.
140. Ogden A.T., Waziri A.E., Lochhead R.A., et al. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery 2008, 62:505-515.
141. Ohgaki H., Kleihues P. Population-based studies on incidence, survival rates, and genetic alterations in astrocytic and oligodendroglial gliomas. J. Neuropathol. Exp. Neurol. 2005, 64:479-489.
142. Ohgaki H., Kleihues P. Genetic pathways to primary and secondary glioblastoma. Am. J. Pathol. 2007, 170:1445-1453.
143. Okamoto K., Furusawa T., Ishikawa K., et al. Mimics of brain tumor on neuroimaging: part I. Radiat. Med. 2004, 22:63-76.
144. Okamoto K., Furusawa T., Ishikawa K., et al. Mimics of brain tumor on neuroimaging: part II. Radiat. Med. 2004, 22:135-142.
145. Paraf F., Jothy S., Van Meir E.G. Brain tumor-polyposis syndrome: two genetic diseases?. J. Clin. Oncol. 1997, 15:2744-2758.
146. Parsons D.W., Jones S., Zhang X., et al. An integrated genomic analysis of human glioblastoma multiforme. Science 2008, 321:1807-1812.
147. Pelloski C.E., Ballman K.V., Furth A.F., et al. Epidermal growth factor receptor variant III status defines clinically distinct subtypes of glioblastoma. J. Clin. Oncol. 2007, 25:2288-2294.
148. Perry A., Aldape K.D., George D.H., et al. Small cell astrocytoma: an aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma. Cancer 2004, 101:2318-2326.
149. Phillips H.S., Kharbanda S., Chen R., et al. Molecular subclasses of high-grade glioma predict prognosis, delineate a pattern of disease progression, and resemble stages in neurogenesis. Cancer Cell 2006, 9:157-173.
150. Plotkin M., Eisenacher J., Bruhn H., et al. 123I-IMT SPECT and 1H MR-spectroscopy at 3.0 T in the differential diagnosis of recurrent or residual gliomas: a comparative study. J. Neurooncol. 2004, 70:49-58.
151. Preston-Martin S., Henderson B.E. N-nitroso compounds and human intracranial tumours. IARC Scientific Publ. 1984, 57:887-894.
152. Preston-Martin S., Pogoda J.M., Schlehofer B., et al. An international case-control study of adult glioma and meningioma: the role of head trauma. Int. J. Epidemiol. 1998, 27:579-586.
153. Preston-Martin S. Epidemiology of primary CNS neoplasms. Neurologic Clin. 1996, 14:273-290.
154. Prins R.M., Cloughesy T.F., Liau L.M. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N. Engl. J. Med. 2008, 359:539-541.
155. Proescholdt M.A., Macher C., Woertgen C., et al. Level of evidence in the literature concerning brain tumor resection. Clin. Neurol. Neurosurg. 2005, 107:95-98.
156. Rabinov J.D., Lee P.L., Barker F.G., et al. In vivo 3-T MR spectroscopy in the distinction of recurrent glioma versus radiation effects: initial experience. Radiology 2002, 225:871-879.
157. Rampling R., James A., Papanastassiou V. The present and future management of malignant brain tumours: surgery, radiotherapy, chemotherapy. J. Neurol. Neurosurg. Psychiatry 2004, 75(Suppl 2):ii24-ii30.
158. Roa W., Brasher P.M., Bauman G., et al. Abbreviated course of radiation therapy in older patients with glioblastoma multiforme: a prospective randomized clinical trial. J. Clin. Oncol. 2004, 22:1583-1588.
159. Sabel M., Giese A. Safety profile of carmustine wafers in malignant glioma: a review of controlled trials and a decade of clinical experience. Curr. Med. Res. Opin. Online 2008.
160. Sampson J.H., Archer G.E., Mitchell D.A., et al. Tumor-specific immunotherapy targeting the EGFRvIII mutation in patients with malignant glioma. Semin. Immunol. 2008, 20:267-275.
161. Sanai N., Alvarez-Buylla A., Berger M.S. Neural stem cells and the origin of gliomas. N. Engl. J. Med. 2005, 353:811-822.
162. Sanai N., Berger M.S. Glioma extent of resection and its impact on patient outcome. Neurosurgery 2008, 62:753-766.
163. Sanai N., Berger M.S. Mapping the horizon: techniques to optimize tumor resection before and during surgery. Clin. Neurosurg. 2008, 55:14-19.
164. Sarkar A., Caamano S., Fernandez J.M. The elasticity of individual titin P E V K exons measured by single molecule atomic force microscopy. J. Biol. Chem. 2005, 280:6261-6264.
165. Sarkar A., Caamano S., Fernandez J.M. The mechanical fingerprint of a parallel polyprotein dimer. Biophys. J. 2007, 92:L36-L38.
166. Sarkar A., Robertson R.B., Fernandez J.M. Simultaneous atomic force microscope and fluorescence measurements of protein unfolding using a calibrated evanescent wave. Proc. Natl. Acad. Sci. USA 2004, 101:12882-12886.
167. Schneider J.P., Trantakis C., Rubach M., et al. Intraoperative M R I to guide the resection of primary supratentorial glioblastoma multiforme - a quantitative radiological analysis. Neuroradiology 2005, 47:489-500.
168. Schwartzbaum J.A., Fisher J.L., Aldape K.D., et al. Epidemiology and molecular pathology of glioma. Nat. Clin. Pract. Neurol. 2006, 2:494-503.
169. Schwartzbaum J.A., Fisher J.L., Goodman J., et al. Hypotheses concerning roles of dietary energy, cured meat, and serum tocopherols in adult glioma development. NeuroEpidemiology 1999, 18:156-166.
170. Schwartzbaum J.A., Lal P., Evanoff W., et al. Presurgical serum albumin levels predict survival time from glioblastoma multiforme. J. Neurooncol. 1999, 43:35-41.
171. Schüz J., Böhler E., Berg G., et al. Cellular phones, cordless phones, and the risks of glioma and meningioma (Interphone Study Group, Germany). Am. J. Epidemiol. 2006, 163:512-520.
172. Scozzafava J., Johnson E.S., Blevins G. Neurological picture. Demyelinating butterfly pseudo-glioma. J. Neurol. Neurosurg. Psychiatry 2008, 79:12-13.
173. Shaw E.G., Scheithauer B.W., O'Fallon J.R., et al. Oligodendrogliomas: the Mayo Clinic experience. J. Neurosurg. 1992, 76:428-434.
174. Shaw E.G., Scheithauer B.W., O'Fallon J.R., et al. Mixed oligoastrocytomas: a survival and prognostic factor analysis. Neurosurgery 1994, 34:577-582.
175. Shintani T., Hayakawa N., Hoshi M., et al. High incidence of meningioma among Hiroshima atomic bomb survivors. J. Radiat. Res. 1999, 40:49-57.
176. Singh S.K., Clarke I.D., Terasaki M., et al. Identification of a cancer stem cell in human brain tumors. Cancer Res. 2003, 63:5821-5828.
177. Singh S.K., Hawkins C., Clarke I.D., et al. Identification of human brain tumour initiating cells. Nature 2004, 432:396-401.
178. Sinha S., Bastin M.E., Whittle I.R., et al. Diffusion tensor M R imaging of high-grade cerebral gliomas. Am. J. Neuroradiol. 2002, 23:520-527.
179. Stepp H., Beck T., Pongratz T., et al. ALA and malignant glioma: fluorescence-guided resection and photodynamic treatment. J. Environ. Pathol. Toxicol. Oncol. 2007, 26:157-164.
180. Strickler H.D., Rosenberg P.S., Devesa S.S., et al. Contamination of poliovirus vaccines with simian virus 40 (1955-1963) and subsequent cancer rates. JAMA 1998, 279:292-295.
181. Stummer W., Reulen H.J., Novotny A., et al. Fluorescence-guided resections of malignant gliomas - an overview. Acta. Neurochir. Suppl. 2003, 88:9-12.
182. Stupp R., Mason W.P., van den Bent M.J., et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352:987-996.
183. Taphoorn M.J., Stupp R., Coens C., et al. Health-related quality of life in patients with glioblastoma: a randomised controlled trial. Lancet Oncol. 2005, 6:937-944.
184. Tatter S.B. Recurrent malignant glioma in adults. Curr. Treat. Options Oncol. 2002, 3:509-524.
185. Taylor M.D., Bernstein M. Awake craniotomy with brain mapping as the routine surgical approach to treating patients with supratentorial intraaxial tumors: a prospective trial of 200 cases. J. Neurosurg. 1999, 90:35-41.
186. Tedeschi-Blok N., Schwartzbaum J., Lee M., et al. Dietary calcium consumption and astrocytic glioma: the San Francisco Bay Area Adult Glioma Study, 1991-1995. Nutr. Cancer 2001, 39:196-203.
187. Thiagalingam S., Flaherty M., Billson F., et al. Neurofibromatosis type 1 and optic pathway gliomas: follow-up of 54 patients. Ophthalmology 2004, 111:568-577.
188. Thoman W.J., Ammirati M., Caragine L.P., et al. Brain tumor imaging and surgical management: the neurosurgeon's perspective. Top. Magn. Reson. Imaging 2006, 17:121-126.
189. Thompson T.P., Lunsford L.D., Kondziolka D. Distinguishing recurrent tumor and radiation necrosis with positron emission tomography versus stereotactic biopsy. Stereotact. Funct. Neurosurg. 1999, 73:9-14.
190. Toh C.H., Castillo M., Wong A.M., et al. Primary cerebral lymphoma and glioblastoma multiforme: differences in diffusion characteristics evaluated with diffusion tensor imaging. Am. J. Neuroradiol. 2008, 29:471-475.
191. Tonn J.C. Awake craniotomy for monitoring of language function: benefits and limits. Acta. Neurochir. (Wien.) 2007, 149:1197-1198.
192. Tovi M., Hartman M., Lilja A., et al. MR imaging in cerebral gliomas. Tissue component analysis in correlation with histopathology of whole-brain specimens. Acta. Radiol. 1994, 35:495-505.
193. Tovi M., Lilja A., Bergström M., et al. Delineation of gliomas with magnetic resonance imaging using Gd-DTPA in comparison with computed tomography and positron emission tomography. Acta. Radiol. 1990, 31:417-429.
194. Tovi M. MR imaging in cerebral gliomas analysis of tumour tissue
195. Tropine A., Vucurevic G., Delani P., et al. Contribution of diffusion tensor imaging to delineation of gliomas and glioblastomas. J. Magn. Reson. Imaging 2004, 20:905-912.
196. Turcot J., Despres J.P., St Pierre F. Malignant tumors of the central nervous system associated with familial polyposis of the colon: report of two cases. Dis. Colon. Rectum. 1959, 2:465-468.
197. Uhrbom L., Dai C., Celestino J.C., et al. Ink4a-Arf loss cooperates with KRas activation in astrocytes and neural progenitors to generate glioblastomas of various morphologies depending on activated Akt. Cancer Res. 2002, 62:5551-5558.
198. Uhrbom L., Nerio E., Holland E.C. Dissecting tumor maintenance requirements using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat. Med. 2004, 10:1257-1260.
199. Upadhyaya M., Osborn M.J., Maynard J., et al. Mutational and functional analysis of the neurofibromatosis type 1 (NF1) gene. Hum. Genet 1997, 99:88-92.
200. Valtonen S., Timonen U., Toivanen P., et al. Interstitial chemotherapy with carmustine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurg. 1997, 41:44-49.
201. Vescovi A.L., Galli R., Reynolds B.A. Brain tumour stem cells. Nat. Rev. Cancer 2006, 6:425-436.
202. Viapiano M.S., Bi W.L., Piepmeier J., et al. Novel tumor-specific isoforms of BEHAB/brevican identified in human malignant gliomas. Cancer Res. 2005, 65:6726-6733.
203. Viapiano M.S., Matthews R.T. From barriers to bridges: chondroitin sulfate proteoglycans in neuropathology. Trends Mol. Med. 2006, 12:488-496.
204. Vogelbaum M.A. Convection enhanced delivery for treating brain tumors and selected neurological disorders: symposium review. J. Neurooncol. 2007, 83:97-109.
205. Vordermark D., Ruprecht K., Rieckmann P., et al. Glioblastoma multiforme with oligodendroglial component (GBMO): favorable outcome after post-operative radiotherapy and chemotherapy with nimustine (ACNU) and teniposide (VM26). BMC Cancer 2006, 6:247.
206. Vos M.J., Hoekstra O.S., Barkhof F., et al. Thallium-201 single-photon emission computed tomography as an early predictor of outcome in recurrent glioma. J. Clin. Oncol. 2003, 21:3559-3565.
207. Vredenburgh J.J., Desjardins A., Herndon J.E., et al. Phase II trial of bevacizumab and irinotecan in recurrent malignant glioma. Clin. Cancer Res. 2007, 13:1253-1259.
208. Watanabe K., Sato K., Biernat W., et al. Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. Clin. Cancer Res. 1997, 3:523-530.
209. Westphal M., Hilt D.C., Bortey E., et al. A phase 3 trial of local chemotherapy with biodegradable carmustine (BCNU) wafers (Gliadel wafers) in patients with primary malignant glioma. Neuro. Oncol. 2003, 5:79-88.
210. Westphal M., Ram Z., Riddle V., et al. Gliadel wafer in initial surgery for malignant glioma: long-term follow-up of a multicenter controlled trial. Acta. Neurochir. (Wien.) 2006, 148:269-275.
211. Wrensch M., Bondy M.L., Wiencke J., et al. Environmental risk factors for primary malignant brain tumors: a review. J. Neurooncol. 1993, 17:47-64.
212. Wrensch M., Fisher J.L., Schwartzbaum J.A., et al. The molecular epidemiology of gliomas in adults. Neurosurg Focus. 2005, 19:E5.
213. Wrensch M., Minn Y., Chew T., et al. Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro. Oncol. 2002, 4:278-299.
214. Wrensch M., Weinberg A., Wiencke J., et al. Does prior infection with varicella-zoster virus influence risk of adult glioma?. Am. J. Epidemiol. 1997, 145:594-597.
215. Wrensch M., Weinberg A., Wiencke J., et al. Prevalence of antibodies to four herpesviruses among adults with glioma and controls. Am. J. Epidemiol. 2001, 154:161-165.
216. Wrensch M., Weinberg A., Wiencke J., et al. History of Chickenpox and Shingles and Prevalence of Antibodies to Varicella-Zoster Virus and Three Other Herpesviruses among Adults with Glioma and Controls. Am. J. Epidemiol. 2005, 161:929-938.
217. Yan H., Parsons D.W., Jin G., et al. IDH1 and IDH2 Mutations in Gliomas. N. Engl. J. Med. 2009, 360:765-773.
218. Yerli H., Aǧildere A.M., Ozen O., et al. Evaluation of cerebral glioma grade by using normal side creatine as an internal reference in multi-voxel 1H-MR spectroscopy. Diagn. Interv. Radiol. 2007, 13:3-9.
219. Zeng Q.S., Li C.F., Zhang K., et al. Multivoxel 3D proton M R spectroscopy in the distinction of recurrent glioma from radiation injury. J. Neurooncol. 2007, 84:63-69.